How COVID-19 is Bending the Curve on Vaccine & Therapeutic Manufacturing Norms
Summary: The COVID-19 pandemic has posed major challenges to the pharma industry, including the need to compress timelines to achieve regulatory approval and to proactively establish a global supply network capable of delivering billions of doses around the world. Bernie Clark, VP of Marketing and Strategy for Catalent Biologics, discusses the challenges and risks associated with this undertaking and the collaboration and innovation necessary to help combat coronavirus in this Q&A.